Uncomplicated Urinary Tract Infection Market is segmented By Treatment (Antibiotics, Vaccines), By Pathogen Type (Escherichia Coli, Klebsiella Pneumon....
Market Size in USD
CAGR10.23%
Study Period | 2024 - 2031 |
Base Year of Estimation | 2023 |
CAGR | 10.23% |
Market Concentration | High |
Major Players | GlaxoSmithKline, Iterum Therapeutics, Fimbrion Therapeutics, Janssen Pharmaceuticals, Inmunotek |
The uncomplicated urinary tract infection market is estimated to be valued at USD 7.2 Bn in 2024 and is expected to reach USD 14.28 Bn by 2031, growing at a compound annual growth rate (CAGR) of 10.23% from 2024 to 2031. Key factors such as the high and growing geriatric population globally who are prone to urinary tract infections, increasing awareness regarding treatments for urinary tract infections, and the ongoing development of novel drugs are expected to drive the growth of the uncomplicated urinary tract infection market.